Restoring Biological Harmony for Patients with Debilitating Disease
We are harnessing the power of microRNA science to develop therapies that normalize biological pathways and counterbalance disease.
Learn More
DEVELOPMENT PROGRAMS
Our pipeline is focused on serious diseases of high unmet need where the latest discoveries in microRNA biology are challenging traditional drug development paradigms and creating opportunities for novel therapeutic approaches.
MIRAGEN CEO FEATURED IN BIZWEST
miRagen’s CEO Bill Marshall was interviewed by BizWest about his goal to address three disease categories: blood cancers, which include leukemias and lymphomas; pathologic fibrosis; and cardiovascular disease.
READ ARTICLE >
Recent Press Releases
- miRagen Therapeutics Reports Third Quarter 2018 Financial Results and Provides Corporate Update
- Miragen Therapeutics to Present New Cobomarsen Phase 1 Clinical Trial Data at the 2018 American Society of Hematology Annual Meeting
- miRagen Therapeutics to Present at two Investor Conferences in November 2018
- miRagen Therapeutics to Report Third Quarter 2018 Financial Results and Host Conference Call on November 7, 2018
- miRagen Therapeutics Announces the Presentation of Data From Preclinical Studies Demonstrating the Potential Anti-Fibrotic Effect of Remlarsen in the Cornea at the 2018 OLIGO Meeting in Seattle, WA